PharmiWeb Recruiter Blog

• Abbott's CentriMag™ Blood Pump, previously cleared for use up to six hours, now can be used to provide longer-term life support to critically ill patients, providing doctors more time to make critical care decisions
• Abbott's CentriMag™ Pre-connected Pack, which combines a blood pump and oxygenator to form a life support circuit, also received FDA clearance for life support lasting less than six hours, helping physicians provide urgent critical care more efficiently and in fewer steps

ABBOTT PARK, Ill., April 25, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced two new clearances from the U.S. Food and Drug Administration (FDA) for the company's industry-leading life support system. With the new indication, the CentriMag Blood Pump for use with the CentriMag™ System, is now cleared for longer-term use in adults when extracorporeal membrane oxygenation (ECMO) – a type of life support for people whose heart and lungs are not working – is critical to saving their life. Now, the clearance for longer-term support allows physicians more time to assess next steps and make critical care decisions for their patients.

• Investment of 350 million EUR in state-of-the-art research infrastructure is Boehringer Ingelheim’s largest single investment in Germany to date
• Boehringer Ingelheim strengthens innovation power and development of biopharmaceuticals, which account for approx. 50 percent of the company’s research pipeline
• New high-tech facility in Biberach offers attractive workplaces for more than 500 scientists

Boehringer Ingelheim today inaugurated its state-of-the-art Biologicals Development Center (BDC) in Biberach an der Riß, Germany. The new high-tech facility underlines the company’s strong commitment to Germany and Europe as location for research and development (R&D) for the care of patients around the world. With the investment of 350 million EUR, Boehringer Ingelheim significantly enhances its innovation power and development of biopharmaceutical development capabilities in Germany.

Bern, Switzerland and Boston, U.S.A., 21 April, 2023 – RetinAI Medical AG (“RetinAI”), a leader in clinical and imaging data management software and advanced analytics using artificial intelligence (AI) for ophthalmology, is excited to announce a new partnership with Boehringer Ingelheim. The companies aim to improve patient outcomes in geographic atrophy (GA) by combining RetinAI’s Discovery^® platform and AI tools with Boehringer Ingelheim’s research in retinal diseases.

• A balanced mix of international investors commits €600 million to Gilde Healthcare Venture&Growth VI, a transatlantic investment fund
• Gilde Healthcare invests in fast growing companies that enable better care at lower cost, supported by its recently appointed Impact Council
• In three years' time, Gilde Healthcare raised over €1.5 billion across three funds

UTRECHT, Netherlands, April 19, 2023 /PRNewswire/ -- Gilde Healthcare today announces a new investment fund with €600 million in commitments: Gilde Healthcare Venture&Growth VI. The new fund focuses on fast growing companies developing solutions for better care at lower cost. Gilde Healthcare invests in companies in Europe and North America active in digital healthcare, medical technology (MedTech) and therapeutics.

In addition to $3.7 billion investment in Boone County, Lilly will commit $15 million to Ivy Tech to foster a diverse talent pipeline for high-tech manufacturing jobs

• PRA023 is a novel, late-stage candidate for ulcerative colitis and Crohn’s disease and other autoimmune conditions
• Prometheus Biosciences’ comprehensive data set enables target discovery and precision medicine approach in inflammation and immunology

RAHWAY, N.J. & SAN DIEGO--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Prometheus Biosciences, Inc. (“Prometheus”) (Nasdaq: RXDX) today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, has agreed to acquire Prometheus for $200.00 per share in cash for a total equity value of approximately $10.8 billion.

A pioneering biotech firm has secured £13.2 million to fund its mission to develop the world’s first treatment for a rare, incurable and deadly disease.  

• Partnership will leverage Aspect’s proprietary bioprinting technology and Novo Nordisk’s expertise and technology in stem cell differentiation and cell therapy development and manufacturing.
• Aspect to receive 75 million US dollars in initial payments and up to 650 million dollars in future milestone payments per product arising from the collaboration, plus tiered royalties.

Vancouver, BC, Canada and Bagsværd, Denmark, 12 April 2023 – Aspect Biosystems and Novo Nordisk A/S today announced a collaboration, development, and licence agreement to develop bioprinted tissue therapeutics designed to replace, repair, or supplement biological functions inside the body with the aim of delivering a new class of truly disease-modifying treatments for diabetes and obesity.

RAHWAY, N.J.‐‐(3BL MEDIA)‐‐Merck (NYSE: MRK), known as MSD outside of the United States and Canada, has earned a place on the Fortune 100 Best Companies to Work For list for the second time in the past three years. The company also made the list in 2021.

• Aviceda is partnering with world-renowned scientist Professor Christopher Scott and his teams at the Patrick G. Johnson Centre for Cancer Research at Queen’s University Belfast to spearhead development of the next generation of glyco-immune therapeutics.
• Aviceda Executives will participate in a Cancer Showcase Event as part of the 25th Anniversary of the Good Friday Agreement Conference at Queen’s to highlight Northern Ireland’s emerging global reputation in the translational oncology ecosystem.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aviceda Therapeutics, a clinical-stage biotech company focused on developing next-generation immuno-modulators to treat diseases such as cancer, today announced a strategic partnership with the Patrick G Johnston Centre for Cancer Research at Queen’s University Belfast (Queen’s). Aviceda’s HALOS™ (High-Affinity Ligands of Sigelcs) nanotechnology platform, based on an invention from the research team led by Professor Chris Scott, Scientific Co-Founder and Chief Scientific Officer of Aviceda & Interim Dean of Research, Faculty of Medicine, Health, and Life Sciences, at Queen’s, harnesses the power of glycobiology to modulate the innate immune system to develop next-generation breakthrough therapeutics, with a focus on immuno-oncology.